TheTechno Optimist.

xT CDx genomic profilingTempus AI—Tempus agrees to buy Personalis for USD 16.25 a share (about USD 1.5B) to add tumour-informed recurrence testingxT CDx genomic profilingTempus AI—FDA approves tumour-only use of Tempus's 648-gene xT CDx testTempus AI—Tempus Q2 2026 revenue rises 22% to USD 382.5M; full-year guidance about USD 1.6BTempus AI—Tempus reports 2025 revenue of about USD 1.27B, up 83%, and guides to its first positive adjusted EBITDA year

xT CDx genomic profiling

by Tempus AIUS

Give every solid-tumour patient a full genetic readout that points to the right drug or trial, and turn millions of such tests into data that speeds up new cancer drugs.

ScalingStage 5 of 5

FDA-approved for tumour-only and tumour-normal use (May 2026); oncology test volume +31% in Q2 2026.

Updated 20 Jul 2026Checked 11 Oct0 updates this week

Milestones

Next · Personalis acquisition closes
  1. Tempus founded in Chicago2015Complete.
  2. FDA approves xT CDx (tumour plus matched normal)1 May 2023Complete.
  3. Nasdaq listing (TEM)14 Jun 2024Complete.
  4. Ambry Genetics acquisition completedFeb 2025Complete.
  5. FDA approves tumour-only use of xT CDx29 May 2026Complete.
  6. Personalis acquisition closesTarget Q4 2026Current milestone.

Most important updates

Upcoming

  1. Q4 2026Personalis acquisition closes (next)
  2. 2027Price benefit from FDA-approved assay migration begins
Primer